Changfeng Pharmaceutical (02652.HK): The company's leading new inhaled nucleic acid drug development project has been selected as part of the 2025 Jiangsu Province Major Science and Technology Project "Innovative Biopharmaceuticals".

Wisdom Finance and Economics APP news, Changfeng Pharmaceutical (02652.HK) announced that the company-led new inhaled nucleic acid drug development project has recently been selected as the "Innovative Biological Medicine" project of the 2025 Jiangsu Province Science and Technology Major Project. This project focuses on the key challenges of small nucleic acid (siRNA) drugs in lung delivery, aiming to promote the translational research and preclinical development of inhaled nucleic acid candidate drugs.